During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Perrigo Company PLC (NYSE:PRGO)
- Dividend Yield: 7.32%
- Canaccord Genuity analyst Susan Anderson maintained a Buy rating and raised the price target from $17 to $19 on Oct. 30, 2026. This analyst has an accuracy rate of 60%.
- JP Morgan analyst Chris Scott maintained a Neutral rating and cut the price target from $20 to $18 on Dec. 15, 2025. This analyst has an accuracy rate of 72%.
- Recent News: On Nov. 4, Perrigo posted upbeat quarterly results.
- Benzinga Pro’s real-time newsfeed alerted to latest PRGO news.
Bristol-Myers Squibb Co (NYSE:BMY)
- Dividend Yield: 4.06%
- Morgan Stanley analyst Terence Flynn maintained an Underweight rating and cut the price target from $41 to $40 on Oct. 30, 2026. This analyst has an accuracy rate of 74%.
- Piper Sandler analyst David Amsellem maintained an Overweight rating and slashed the price target from $82 to $78 on Oct. 26, 2026. This analyst has an accuracy rate of 79%
- Recent News: On Oct. 29, Bristol-Myers Squibb posted upbeat quarterly results.
- Benzinga Pro’s real-time newsfeed alerted to latest BMY news
GSK plc (NYSE:GSK)
- Dividend Yield: 3.65%
- Jefferies analyst Michael Leuchten downgraded the stock from Buy to Hold and cut the price target from $67.4 to $55.9 on Oct. 29, 2026. This analyst has an accuracy rate of 64%.
- Barclays analyst James Gordon downgraded the stock from Equal-Weight to Underweight on Jan. 6, 2026. This analyst has an accuracy rate of 73%.
- Recent News: On Oct. 29, GSK posted better-than-expected quarterly results.
- Benzinga Pro’s real-time newsfeed alerted to latest GSK news
Photo via Shutterstock